Oligonucleotide– tag –
-
Gilead Report Highlights RNA Therapeutic Progress: GSK/Ionis HBV ASO Shows Positive Phase 3, Novartis FSHD siRNA Promising Early Data
The Bio Report USA Overview A Gilead report underscores significant advancements in RNA therapeutic clinical trials, with GSK/Ionis's beoprovirsen, an ASO targeting HBV, demonstrating positive Phase 3 results. Novartis's siRNA therapy, D... -
SynaptixBio Accelerates Regulatory Pathway for Ultra-Rare ASO Drugs, Expanding Therapeutic Potential of TUBB4A Mutant Silencers
Advancing RNA USA Overview SynaptixBio is effectively navigating the regulatory landscape for ultra-rare antisense oligonucleotide (ASO) drugs, securing Orphan Drug and Rare Pediatric Disease designations in collaboration with the FDA, E... -
Comprehensive Guide Published: RNA Therapeutics, from ASO to LNP/GalNAc Platforms, Shaping the Future of Precision Medicine
MDPI International Overview A comprehensive guide published by MDPI overviews the engineering history of RNA therapeutics, spanning from ASOs to modern siRNA and mRNA-LNP-based therapies. It highlights a growing regulatory trend favoring... -
Japan Accelerates Next-Gen mRNA Vaccine and Therapeutic Development: saRNA and circRNA Boost Immunity and Efficiency
MJA InSight Australia Overview Research into next-generation mRNA vaccines, particularly self-amplifying RNA (saRNA) and circular RNA (circRNA), is rapidly advancing, focusing on enhancing immune durability and efficiency. Beyond infecti... -
Wave Life Sciences’ Obesity Drug WVE-007 Achieves 15% Visceral Fat Reduction in Phase 1, Advancing to Phase 2; AATD RNA Editing Therapy WVE-006 Anticipates Accelerated Approval
BigGo Finance USA Overview Wave Life Sciences' experimental siRNA therapy, WVE-007, successfully reduced visceral fat by 15% after a single injection in Phase 1 trials and has initiated Phase 2a. This drug targets the INHBE gene in the l... -
FDA Approves Dawnzera: RNA-Targeting ASO Marks Paradigm Shift for Hereditary Angioedema
Liv Hospital Turkey Overview In August 2025, the FDA granted approval to Dawnzera (donidalorsen-azyh), a groundbreaking RNA-targeting antisense oligonucleotide (ASO) for hereditary angioedema (HAE). By specifically silencing prekallikrei... -
Dual-Targeting Lipid Nanoparticles Drastically Enhance β Cell-Specific RNA Delivery, Promising for Type 1 Diabetes Therapy
ACS Publications USA Overview Researchers have developed a dual-targeting lipid nanoparticle (LNP) engineering strategy that significantly enhances β cell-directed RNA delivery. This novel LNP demonstrated substantially improved in vivo ... -
6th mRNA Therapeutics Summit Highlights Shift to Oncology, with In Vivo CAR-T, saRNA, and circRNA as Key Innovations
BioSpace USA Overview The 6th mRNA-Based Therapeutics Summit revealed a significant shift in mRNA clinical activity from infectious diseases to oncology, with in vivo CAR-T emerging as a notable application. Self-amplifying RNA (saRNA) a... -
New England Biolabs Unveils Comprehensive RNA Workflow Reagents Supporting mRNA Therapeutics and Diagnostics
New England Biolabs USA Overview New England Biolabs has announced an expanded portfolio of reagents to support various RNA research workflows, including mRNA therapeutics, personalized medicine, and diagnostics. The company highlights t... -
AI-Driven CRISPR Design: Revolutionizing Gene Editing with Enhanced Precision and Efficiency
Preprints.org International Overview A comprehensive review systematically investigates AI-driven tools and methodologies for CRISPR design, highlighting AI's role in significantly enhancing gene editing precision, efficiency, and automa...
